Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Pressure BioSciences (OTCMKTS:PBIO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Earnings and Valuation
This table compares Lucid Diagnostics and Pressure BioSciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 49.03 | -$58.01 million | ($0.96) | -1.36 |
| Pressure BioSciences | $1.98 million | 0.03 | -$29.31 million | ($0.96) | 0.00 |
Analyst Recommendations
This is a summary of current recommendations and price targets for Lucid Diagnostics and Pressure BioSciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Pressure BioSciences | 0 | 0 | 0 | 0 | 0.00 |
Lucid Diagnostics currently has a consensus price target of $4.13, indicating a potential upside of 216.09%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Lucid Diagnostics is more favorable than Pressure BioSciences.
Institutional and Insider Ownership
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 0.0% of Pressure BioSciences shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 10.8% of Pressure BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Lucid Diagnostics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Pressure BioSciences has a beta of -0.8, suggesting that its stock price is 180% less volatile than the S&P 500.
Profitability
This table compares Lucid Diagnostics and Pressure BioSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -1,426.27% | N/A | -95.51% |
| Pressure BioSciences | N/A | N/A | N/A |
Summary
Lucid Diagnostics beats Pressure BioSciences on 7 of the 12 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Pressure BioSciences
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
